Non-inferior survival and enhanced longevity with initial low-dose versus full-dose enzalutamide: a single-centre real-world prostate cancer study
Background: Prostate cancer enzalutamide treatment is approved at a standard dose of 160 mg daily. Concerns for real-world patients -- older and more fragile than those enrolled in clinical trials -- have prompted consideration of initiating treatment with lower doses, but the long-term efficacy of this approach remain...